Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
Teja Voruganti, Pamela R. Soulos, Ronac Mamtani, et al.
JAMA Oncology (2023) Vol. 9, Iss. 3, pp. 334-334
Closed Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Immunotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: Challenges and Perspectives
Anass Baladi, Hassan Abdelilah Tafenzi, Othmane Zouiten, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2120-2120
Open Access | Times Cited: 1
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e007987-e007987
Open Access | Times Cited: 8
Tackling Non–Small Cell Lung Cancer in Young Adults: From Risk Factors and Genetic Susceptibility to Lung Cancer Profile and Outcomes
Juan Carlos Laguna, Marco Tagliamento, Matteo Lambertini, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
Older adults with cancer and common comorbidities—challenges and opportunities in improving their cancer treatment outcomes
Weiwei Chen, Rachel D. Altshuler, Phil Daschner, et al.
JNCI Journal of the National Cancer Institute (2024) Vol. 116, Iss. 11, pp. 1730-1738
Closed Access | Times Cited: 4
Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
Jie Yao, Xuwen Lin, Xin Zhang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 4
Trends in Immunotherapy (IO) Use and Survival Among Patients With High‐Incidence Stage IV Cancers Across the United States
Samantha Warwar, Lauren M. Janczewski, Gladys M. Rodriguez, et al.
Journal of Surgical Oncology (2025)
Open Access
Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare
Joshua A. Roth, David Kratochvil, Stephanie Dorman, et al.
Journal of Medical Economics (2025), pp. 1-16
Open Access
Immune Checkpoint Inhibitors in Geriatric Oncology
Sarah Cook, Md Al Amin, Shahla Bari, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 5, pp. 562-572
Closed Access | Times Cited: 3
Increasing serum complement component 1q is associated with worse prognosis in advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a single-center, retrospective study
Jiazhuo Tang, Fu Yang, Yuxiao Song, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 5, pp. 3251-3259
Open Access | Times Cited: 2
Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, et al.
JTO Clinical and Research Reports (2023) Vol. 4, Iss. 6, pp. 100524-100524
Open Access | Times Cited: 6
The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysis
Jiaxin Yin, Yuxiao Song, Yang Fu, et al.
Aging (2023) Vol. 15, Iss. 24, pp. 15025-15049
Open Access | Times Cited: 5
Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer
Nikki M. Carroll, Jennifer Eisenstein, Andrea N. Burnett‐Hartman, et al.
Cancer Treatment and Research Communications (2023) Vol. 36, pp. 100730-100730
Open Access | Times Cited: 4
Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting
David Waterhouse, Candice Yong, Andrew J. Frankart, et al.
Future Oncology (2023) Vol. 19, Iss. 28, pp. 1905-1916
Open Access | Times Cited: 4
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)
Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, et al.
Lung Cancer (2024) Vol. 194, pp. 107896-107896
Closed Access | Times Cited: 1
Predictive value of serum magnesium levels for prognosis in patients with non-small cell lung cancer undergoing EGFR-TKI therapy
Fangzhou Xu, Fu-Rong Meng, Wan-Jing Li, et al.
Open Life Sciences (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 1
Survival Improvement of Stage IV Non-small Cell Lung Cancer in the Immunotherapy Era: A Retrospective Cohort Study in a US Population
Lianfang Ni, Zhigang Zhang, Dan Sun, et al.
Advances in Therapy (2024) Vol. 41, Iss. 12, pp. 4591-4600
Closed Access | Times Cited: 1
Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma
Jing Yong, Dongdong Wang, Huiming Yu
Translational Cancer Research (2024) Vol. 13, Iss. 7, pp. 3217-3241
Open Access | Times Cited: 1
Identification of age‐ and immune‐related gene signatures for clinical outcome prediction in lung adenocarcinoma
Andrew Zhou, Dalin Zhang, Xiaoman Kang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 16, pp. 17475-17490
Open Access | Times Cited: 3
The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review
Kenji Morimoto, Tadaaki Yamada, Koichi Takayama
Translational Lung Cancer Research (2023) Vol. 12, Iss. 11, pp. 2310-2321
Open Access | Times Cited: 3
Long-term survival in patients with brain-only metastatic non-small cell lung cancer undergoing upfront intracranial stereotactic radiosurgery and definitive treatment to the thoracic primary site
Kamran Salari, J.S. Lee, H. Ye, et al.
Radiotherapy and Oncology (2024) Vol. 196, pp. 110262-110262
Closed Access
Trends in the use of immunotherapy to treat soft tissue sarcoma
Yoshiko Iwai, Xavier L. Baldwin, Timothy Feeney, et al.
The American Journal of Surgery (2024) Vol. 236, pp. 115794-115794
Closed Access
Single-cell analysis reveals the disparities in immune profiles between younger and elder patients
Huixing Dong, Feng Hu, Bo Hao, et al.
European Geriatric Medicine (2024)
Closed Access
Treatment Patterns and Health Care Resource Utilization of Patients With Non–Small Cell Lung Cancer in Puerto Rico: The TREATLINES-ONCOLUNG Study
Edgar I. Miranda, Axel Gierbolini-Bermúdez, Rafael Quintana, et al.
JCO Global Oncology (2024), Iss. 10
Open Access
Heterogeneity between subgroups of first-line chemoimmunotherapy for extensive-stage small cell lung cancer patients: a meta-analysis and systematic review
Wenwen Kang, Jing Cheng, Lanlan Pan, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Pan‐Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System
Sean R. Miller, Matthew J. Schipper, Lars G. Fritsche, et al.
Cancer Medicine (2024) Vol. 13, Iss. 21
Open Access
Page 1 - Next Page

Scroll to top